Article
New HPV Vaccine Can Protect Against 80% of Cervical Cancers, Study Estimates
The study, published in the Journal of the National Cancer Institute found that in addition to protecting against 80% of cervical cancers, the new Gardasil-9 has the potential to protect against nearly 19,000 other cancers diagnosed in the United States.
The new 9-valent human papillomavirus (HPV) vaccine, can potentially prevent 80% of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus.
In addition to protecting against 80% of cervical cancers, the new 9-valent HPV vaccine, which includes 7 cancer causing HPV-types—16,18, 31, 33, 45, 52, and 58—has the potential to protect against nearly 19,000 other cancers diagnosed in the United States, including anal, oropharyngeal, and penile cancers. This is a 13% increase in protection against HPV-related cancers in comparison to the first vaccines on the market, Gardasil and Cervarix, which protected against HPV types 16 and 18. These findings come from a 7-center study published in the Journal of the National Cancer Institute. The CDC initiated the research effort, in conjunction with Cedars-Sinai.
Read the article on MedicalXpress: http://bit.ly/1HbBUaD
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
